Tracking business by indication is critical for evaluating market performance and making accurate resource allocations
Patrick Angelastro
Advertisement
Articles by Patrick Angelastro
When rebate strategies are coupled with sales force and DTC spending, it results in "margin-negative" business-that is, sales that bring in less than the marginal cost of selling, promoting, and manufacturing the drug.
Advertisement
Latest Updated Articles
Special Report: Platform Drugs—Marketing Your OpportunitiesPublished: May 1st 2008 | Updated:
No Margin for ErrorPublished: September 1st 2005 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
2
Could DTC Programs Help Simplify the Drug-Pricing System?
3
Lilly Enters Definitive Agreement Acquiring Aderum Biotechnologies
4
AI Becomes Pharma’s New Operating System: Q&A with causaLens’ CEO and Co-Founder Darko Matovski
5
